Tokai Pharmaceuticals to Present at 2015 JMP Securities Life Sciences Conference

BOSTON--(BUSINESS WIRE)-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that Lee Kalowski, Chief Financial Officer, will present at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015 at 12:30 pm ET, at The St. Regis New York in New York City.

A live webcast of the JMP Securities presentation can be accessed under the “Calendar of Events” page within the Investors & Media section of the company’s website at www.tokaipharma.com. A replay of the webcast will be archived on the Tokai website for 90 days following the date of the presentation.

About Tokai Pharmaceuticals

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases. The company’s lead drug candidate, galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate being developed for the treatment of patients with castration-resistant prostate cancer. The Company’s ARDA drug discovery program is focused on the identification and evaluation of compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation and are targeted to patients with androgen receptor signaling diseases, including prostate cancer. For more information on the company and galeterone, please visit www.tokaipharma.com.

Forward-looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, intellectual property, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the Company’s cash resources will be sufficient to fund the Company’s continuing operations for the period anticipated; whether data from early clinical trials will be indicative of the data that will be obtained from future clinical trials; whether galeterone will advance through the clinical trial process on the anticipated timeline, including whether ARMOR3-SV will be initiated when anticipated; whether a companion diagnostic can be developed successfully and on a timely basis; whether the results of ARMOR3-SV will warrant submission for regulatory approval of galeterone and whether such submission will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if galeterone obtains such approval, it will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of the Company’s quarterly report on Form 10-Q for the three months ended March 31, 2015. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any subsequent date. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150618005193/en/

Investors:
Tokai Pharmaceuticals
Lee Kalowski, 617-225-4305
Chief Financial Officer
or
Argot Partners
David Pitts, 212-600-1902
[email protected]
or
Media:
Pure Communications, Inc.
Susan Heins, 864-286-9597

Source: Tokai Pharmaceuticals

You May Also Be Interested In

• Cal-Maine Foods Releases Fiscal Year 2025 Impact Report
• Cushman & Wakefield: U.S. Life Sciences Market Moves Toward Rebalancing as Capital Returns and New Development Slows
• NEUBERGER REAL ESTATE SECURITIES INCOME FUND ANNOUNCES MONTHLY DISTRIBUTION